Research Sample bioBank
Non-small cell lung cancer (NSCLC) Clinical Research Samples
Discovery Life Sciences provides the highest quality Non-small cell lung cancer (NSCLC) Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Non-small cell lung cancer (NSCLC) Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
|Product ID||Sample||Origin||Matrix||Vial (ml)||Quantity||Price||Age||Gender||Ethnicity||Storage Temp||Sample Date||Test 1||Test Data 1||Detail 1||Test 2||Test Data 2||Detail 2||Test 3||Test Data 3||Detail 3||Product|
|Blood Type||Current Medications||Smoking Notes||ICD10 codes||Site of Primary Tumor||Site of Metastasis||History of Benign Disease Prior to Cancer Diagnosis||Any Previous Form of Cancer||Biomarker testing Information|
|BBS0000-M2900100785100218DD||Non-small cell lung cancer (NSCLC)||United States||Serum||1.00||6.00||$250.00||75 Y||Female||Non-Hispanic||<-70C||02-Oct-18||Clinical Diagnosis||Metastatic NSCLC||Any Previous Form of Cancer?||No||Date of Initial Primary Tumor Diagnosis||26-Apr-16||$250.00||Unknown||Azithromycin, dexamthasone, diltiazem, folic acid, hydrochlorothiazide, levothyroxine, medical marijuana, Medrol Dosepak, metformin, protonix, warfarin||Previous- 60-pack-years||Right lung||Bilateral Lung, possibly bone||Hypertension, type II diabetes, hypothyroidism||No||CEA: 5.1 ng/Ml|
|BBS0000-Y9900111010021017DD||Non-small cell lung cancer (NSCLC)||United States||Serum||1.00||3.00||$250.00||61 Y||Female||Non-Hispanic||<-70C||10-Feb-17||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||Stage I, T1N0M0,||10-Feb-17||Date of Initial Primary Tumor Diagnosis||18-Jan-17||$250.00||Unknown||Albuterol, Norvasc, Aspirin, Symbicort, Klonopin, Lexapro, Flonase, HydroDIURIL, Duoneb, Lisinopril, Claritin, Lopressor, Singulair, Centrum Silver, Prilosec, Spiriva , Zanaflex | Hepatitis C||Former 2 packs/day for 46 years||Upper Lobe Mass in Right Lung||N/A||N/A||No||BRAF-V600E, Negative for mutation 20-Jan-2017 | KRAS Mutational Analysis: Mutation Identified 20-Jan-2017|
|BBS0005-AA900061078072816DD||Non-small cell lung cancer (NSCLC)||Russia||0.5 mL Serum||1.00||1.00||$250.00||46 Y||Male||Non-Hispanic||<-70C||28-Jul-16||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||II; T2N1M0G3||3-Aug-16||Date of Initial Primary Tumor Diagnosis||12-Jul-16||$250.00||Unknown||None||Current; 15-20 per day||Left Lung||N/A||No||No||N/A|
|BBS0005-AA900061090072116DD||Non-small cell lung cancer (NSCLC)||Russia||0.5 mL Serum||3.00||$250.00||54 Y||Male||Non-Hispanic||<-70C||21-Jul-16||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||II; T2N0M0G2||26-Jul-16||Date of Initial Primary Tumor Diagnosis||13-Jul-16||$250.00||Unknown||None||Current; 20-30 per day||Right Lung||N/A||No||No||N/A|
|BBS0005-AA900061091072216DD||Non-small cell lung cancer (NSCLC)||Russia||0.5 mL Serum||1.00||1.00||$250.00||77 Y||Male||Non-Hispanic||<-70C||22-Jul-16||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||II; T2N0M0G3||26-Jul-16||Date of Initial Primary Tumor Diagnosis||7-Jul-16||$250.00||Unknown||None||Current; 10-30 per day||Left Lung||N/A||No||No||N/A|
|BBS0005-AA900061092102016DD||Non-small cell lung cancer (NSCLC)||Russia||0.5 mL Serum||1.00||2.00||$250.00||60 Y||Female||Non-Hispanic||<-70C||20-Oct-16||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||II; T2N0M0G3||25-Oct-16||Date of Initial Primary Tumor Diagnosis||7-Oct-16||$250.00||Unknown||None||Current; 10-20 per day||Right Lung||N.A||No||No||N/A|
|BBS0005-AA900061093070816DD||Non-small cell lung cancer (NSCLC)||Russia||0.5 mL Serum||1.00||1.00||$250.00||65 Y||Male||Non-Hispanic||<-70C||08-Jul-16||Clinical Diagnosis||Non Small Cell Lung Cancer||Pre-Treatment||Staging||III; T3N1M0G4||13-Jul-16||Date of Initial Primary Tumor Diagnosis||21-Jun-16||$250.00||Unknown||None||Current; 20-30 per day||Right Lung||N/A||No||No||N/A|
|BBS0005-M2900020371092118DD||Non-small cell lung cancer (NSCLC)||United States||0.5 mL Serum||1.00||9.00||$250.00||61 Y||Female||Non-Hispanic||<-70C||21-Sep-18||Clinical Diagnosis||NSCLC||Any Previous Form of Cancer?||Breast||Date of Initial Primary Tumor Diagnosis||27-Apr-18||$250.00||Unknown||Amitriptylene, calcium, cyclobenzaprine, folic acid, medical marijuana, neurontin, ondansetron, oxycodone, percocet, prochlorperazine||Current||medial aspect of right upper lobe||NA||Osteoarthritis, carpal tunnel syndrome, peptic ulcer disease, IBS||Breast||None|
|BBS0005-M2900020373092618DD||Non-small cell lung cancer (NSCLC)||United States||0.5 mL Serum||1.00||2.00||$250.00||63 Y||Female||Non-Hispanic||<-70C||26-Sep-18||Clinical Diagnosis||NSCLC||Any Previous Form of Cancer?||No||Date of Initial Primary Tumor Diagnosis||18-Aug-15||$250.00||Unknown||CBD, docusate sodium, levothyroxine, lexapro, lorazepam, lyrica, multivitamin, nasal saline, ProAir, Restoril, simvastatin, Voltaren, Zofran||Current- 40-pack-years||right upper lobe||mediastinum, retroperitoneum, lymph nodes, bilateral neck, chest, peripancreatic area||Fibromyalgia, hyperlipemia, COPD||No||None|
|BBS0005-M2900020374111518DD||Non-small cell lung cancer (NSCLC)||United States||0.5 mL Serum||1.00||3.00||$250.00||65 Y||Male||Unknown||<-70C||15-Nov-18||Clinical Diagnosis||NSCLC||Staging||T3NxMx||27-Jul-18||Date of Initial Primary Tumor Diagnosis||4-Feb-13||$250.00||Unknown||Acetaminophen, dexamethasone, hydrocodone, ibuprofen, lorazepam, ondansetron, proAir, prochlorperazine||Previous, 90-pack-years||Right Upper Lobe and Right Lower Lobe- 2 separate primaries||U/A||type II diabetes, CAD, hypertension, dyslipidemia||U/A||U/A|
|BBS0005-M2900020564082418DD||Non-small cell lung cancer (NSCLC)||United States||0.5 mL Serum||1.00||2.00||$250.00||49 Y||Female||Non-Hispanic||<-70C||24-Aug-18||Clinical Diagnosis||NSCLC||Most Recent Staging||T1N2M0||Date of Initial Primary Tumor Diagnosis||4/28/2018||$250.00||Unknown||Omeprazole 20mg, Keppra 500mg, Topamax 100mg, LaMICtal150mg, LaMICtal 100mg||Current; 48-pack-years||Right Middle Lobe of Lung||U/A||U/A||Yes; NSCLC 08/2016|
|BBS0005-P6900088866012519DD||Non-small cell lung cancer (NSCLC)||United States||0.5 mL Serum||1.00||9.00||$250.00||71 Y||Female||Non-Hispanic||<-70C||25-Jan-19||Clinical Diagnosis||Non-small cell lung cancer (adenosquamous histology)||Staging||Ib; T2N0M0||8-Nov-18||Date of Initial Primary Tumor Diagnosis||23-Oct-18||$250.00||Unknown||Warfarin, Albuterol, Amiodarone, Amlodipine, Aspirin, Atorvastatin, Calcium carbonate, Doxycycline, Gabapentin, Metoprolol tartrate, Prednisone, Eye Vitamin and Minerals||Former 2 packs/day for 43 years||Right lung, upper lobe||N/A||No||No||None|
|EDP0000-AA900040117112017DD||Non-small cell lung cancer (NSCLC)||Russia||K2 EDTA Plasma||1.00||1.00||$250.00||67 Y||Female||Non-Hispanic||<-70C||20-Nov-17||Clinical Diagnosis||Adenocarcinoma||Pre-Treatment||Staging||IIIa; T3N2M0G3||26-Nov-17||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||2-Nov-17||$250.00||Unknown||L-Thyroxine, Diltiazem, Enalapril||None||C34.11||Right lung, (upper lobe)||N/A||No||No||None|
|EDP0000-AA900082617090817DD||Non-small cell lung cancer (NSCLC)||Russia||K2 EDTA Plasma||1.00||2.00||$250.00||71 Y||Female||Non-Hispanic||<-70C||08-Sep-17||Clinical Diagnosis||Squamous Cell Lung Carcinoma||Pre-Treatment||Staging||Stage Iib; T3N0M0G2||13-Sep-17||Date of Initial Primary Tumor Diagnosis||15-Aug-17||$250.00||Unknown||N/A||None||C34.11||Right lung (lower lobe)||N/A||No||No||None|
|EDP0000-AA900082619073117DD||Non-small cell lung cancer (NSCLC)||Russia||K2 EDTA Plasma||1.00||2.00||$250.00||64 Y||Male||Non-Hispanic||<-70C||31-Jul-17||Clinical Diagnosis||Squamous Cell Lung Carcinoma||Pre-Treatment||Staging||Stage IIIb; T4N2M0G2||3-Aug-17||Date of Initial Primary Tumor Diagnosis||18-Jul-17||$250.00||Unknown||N/A||Current 10-15 cigs/day for 40 years||C34.11||Right lung (upper lobe)||N/A||Chronic Bronchitis||No||None|
|EDP0000-AA900082620072517DD||Non-small cell lung cancer (NSCLC)||Russia||K2 EDTA Plasma||1.00||1.00||$250.00||61 Y||Male||Non-Hispanic||<-70C||25-Jul-17||Clinical Diagnosis||Bronchoalveolar Adenocarcinoma||Pre-Treatment||Staging||Stage Iib; T2N1M0G1||28-Jul-17||Date of Initial Primary Tumor Diagnosis||10-Jul-17||$250.00||Unknown||N/A||Current 10-20 cigs/day for 30 years||C34.11||Right lung||N/A||Chronic Bronchitis||No||None|
|RUI0000-AI900019043082819DD||Non-small cell lung cancer (NSCLC)||United States||Raw Urine||3.50||1.00||$75.00||62 Y||Male||Non-Hispanic||<-70C||28-Aug-19||Diagnosis||Non Small Cell Carcinoma||Pre-Treatment||$75.00||Unknown|
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.